Rapid Point-of-Care Testing for Genital Tract Inflammatory Cytokine Biomarkers to Diagnose Asymptomatic Sexually Transmitted Infections and Bacterial Vaginosis in Women: Cost Estimation and Budget Impact Analysis.
Rapid Point-of-Care Testing for Genital Tract Inflammatory Cytokine Biomarkers to Diagnose Asymptomatic Sexually Transmitted Infections and Bacterial Vaginosis in Women: Cost Estimation and Budget Impact Analysis.
复制标题
DOI：
10.1097/olq.0000000000001565
复制
发表时间：
2022-03-01
影响因子：
3.1
通讯作者：
Sinanovic E
中科院分区：
文献类型：
--
作者：
Kairu A;Masson L;Passmore JS;Cunnama L;Sinanovic E
对南非开普敦正在开发的用于妇女生殖器炎症筛查的细胞因子生物标记物快速检测设备(生殖器炎症检测)的一项研究估计，在现有计划生育服务中实施该设备将增加成本。文本中提供了补充的数字内容。生殖器炎症筛查可以显示性传播感染(STI)和细菌性阴道病(BV)的无症状病例，这在只有综合征治疗的情况下很有用。这项研究旨在估计使用一种新的细胞因子生物标记物快速测试进行筛查的增量成本，并确定在南非初级卫生机构提供这项服务的预算影响。据估计，2016年前往3个不同计划生育诊所就诊的妇女(15-49岁)在现有计划生育服务中增加生殖器炎症筛查的费用为1美元。从提供者的角度筛选的每个患者的预测单位成本是使用自下而上和自上而下的方法计算的，并用于分析在全国范围内扩大规模并在初级卫生设施提供这项服务的预算影响。单变量敏感性分析测试了研究结果的稳健性。筛查生殖器炎症的每名妇女的增量费用在3.19美元到4.79美元之间。扩大的费用从每年7,245,775美元到全国22,212,636美元不等。这是基于目前在所有初级卫生保健机构寻求避孕服务的育龄妇女的人数，作为最容易感染无症状性传播感染/BV的人的代表。费用估计数对人员费用、使用率和人口覆盖率的变化很敏感。除了降低妇女感染艾滋病毒的风险外，这一筛查工具还可能提高病例发现率，有助于更好地管理和控制STI/BV。增量费用估计数可使实施费用负担得起。
A study of a cytokine biomarker rapid test device being developed for genital inflammation screening in women (Genital Inflammation Test) in Cape Town, South Africa, estimated incremental costs for its implementation to existing family planning services. Supplemental digital content is available in the text. Screening for genital inflammation can reveal asymptomatic cases of sexually transmitted infections (STIs) and bacterial vaginosis (BV), useful in settings where only syndromic management is available. This study aimed to estimate the incremental cost of screening using a new cytokine biomarker rapid test and determine the budget impact of providing this service in primary health facilities in South Africa. Costs of adding genital inflammation screening to existing family planning services were estimated for women (15–49 years) attending 3 different family planning clinics in US $2016. The predicted unit cost per patient screened from a provider's perspective was calculated using bottom-up and top-down approaches and was used to analyze the budget impact of scaling up and providing this service in primary health facilities countrywide. Univariate sensitivity analyses tested the robustness of the findings. The incremental cost per woman screened for genital inflammation ranged between US $3.19 and US $4.79. The scaled-up costs ranged between US $7,245,775 and US $22,212,636 countrywide, annually. This was based on the number of women of reproductive age currently seeking contraceptive care at all primary health care facilities, as a proxy for those most susceptible to asymptomatic STIs/BV. The cost estimates were sensitive to changes in personnel costs, utilization rate, and population coverage rates. This screening tool is likely to increase case detection, contributing to better STI/BV management and control, in addition to reducing women's risk of HIV acquisition. The incremental cost estimates could make implementation affordable.